Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR)

American Journal of Nephrology
Joachim HertelPaul Audhya

Abstract

Darbepoetin alfa, an effective treatment for anemia of chronic kidney disease (CKD), can be administered at extended intervals. Simplify the Treatment of Anemia with Aranesp (STAAR), a multicenter, 52-week study, was conducted to assess the efficacy of darbepoetin alfa administered subcutaneously every other week (Q2W) in maintaining hemoglobin (Hb) in CKD patients not receiving dialysis. This is a subgroup analysis of subjects converted from once-weekly (QW) recombinant human erythropoietin (rHuEPO; US Aranesp package insert) and who received up to 52 weeks of darbepoetin alfa therapy (evaluation period 20-32 weeks). Enrolled subjects had a creatinine clearance < or = 70 ml/min or an estimated glomerular filtration rate < or = 60 ml/min and transferrin saturation > or = 20%. Darbepoetin alfa doses were titrated to maintain Hb levels < or = 12 g/dl. The primary endpoint was mean Hb during evaluation. There were 524 subjects enrolled in the study who were previously receiving rHuEPO QW. Mean Hb +/- standard deviation was 11.2 +/- 1.27 g/dl at baseline, and the least squares mean +/- SE was 11.4 +/- 0.04 during evaluation. The mean +/- SD Q2W darbepoetin alfa dose was 49.7 +/- 21.9 microg at baseline and 48.9 +/- 35.5 microg at e...Continue Reading

References

Apr 1, 1995·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·D A RevickiR L Benz
Jul 13, 1999·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·A LevinO Djurdjev
Mar 7, 2001·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
Sep 29, 2001·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·W H KazmiB J Pereira
Oct 5, 2001·Journal of the American College of Cardiology·A Al-AhmadM J Sarnak
Jun 26, 2002·Kidney International·Samina S KhanAnnamaria T Kausz
Jul 2, 2002·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Joseph W EschbachJohn C Stivelman
Jul 31, 2002·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Paolo AltieriAntonello Pani
Oct 19, 2002·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Gregorio T Obrador, Brian J G Pereira
Oct 25, 2002·Journal of the American Society of Nephrology : JASN·Chi-Yuan HsuGary C Curhan
Dec 14, 2002·American Journal of Nephrology·Michael G SuranyiRowan Walker
Dec 25, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Josef CoreshAndrew S Levey
Mar 4, 2003·Nature Biotechnology·Steve ElliottJoan Egrie
Jul 1, 2004·Clinical Nephrology·R ProvenzanoUNKNOWN POWER Study Group
Sep 24, 2004·The New England Journal of Medicine·Nagesh S AnavekarMarc A Pfeffer
Sep 24, 2004·The New England Journal of Medicine·Alan S GoChi-yuan Hsu
Dec 23, 2004·Kidney International. Supplement·Marian GoicoecheaJosé Luño
Jun 30, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Michael GermainMario Curzi

❮ Previous
Next ❯

Citations

Dec 6, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Jan-Christoph GalleMourad Farouk
Apr 25, 2008·American Journal of Nephrology·Janice P LeaLawrence Agodoa
May 31, 2012·Journal of Drug Delivery·Shashwat S BanerjeeJayant Khandare
May 1, 2008·Expert Review of Clinical Pharmacology·Anil K Agarwal
Mar 25, 2009·Expert Opinion on Drug Safety·Anil K Agarwal
Oct 7, 2006·Current Medical Research and Opinion·Jeffrey HoggardPaul Audhya
Nov 14, 2006·Journal of the American Medical Directors Association·Anil K Agarwal
May 18, 2016·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Jan-Christoph GalleChristopher Winearls
Jul 10, 2009·The Cochrane Database of Systematic Reviews·Julia BohliusAndreas Engert
Dec 14, 2012·The Cochrane Database of Systematic Reviews·Thomy ToniaJulia Bohlius
Dec 3, 2016·Saudi Journal of Kidney Diseases and Transplantation : an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia·Fatma Al RaisiFaissal A M Shaheen
Feb 7, 2020·International Journal of Clinical Pharmacy·Masaki HigashiuraTakashi Shigematsu
Aug 5, 2008·The American Journal of Geriatric Pharmacotherapy·Marcia R SilverCatherine Stehman-Breen
Jul 16, 2010·Heart Failure Clinics·Tejas V Patel, Ajay K Singh
May 31, 2011·Néphrologie & thérapeutique·Jacques B Rottembourg, Aurélie Dansaert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.